Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders

-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept datasets expected mid-2027 -- -- Strong financial position with approximately $535 million of cash and cash equivalents as of February 28, 2026, with anticipated runway into Phase 3 development of DMR-001 -- BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ...